The rising number of monkeypox and the high demand for its effective emergency treatment are projected to boost the growth of United Kingdom monkeypox therapeutics market in the forecast period, 2023-2027.
According to TechSci Research report, “United Kingdom Monkeypox Therapeutics Market – By Region, Competition Forecast & Opportunities, 2027”, the United Kingdom monkeypox therapeutics market is expected to witness growth at a significant rate in 2023-2027. Money pox is a rare, usually mild infection, which is caught from infected wild animals in parts of Africa. It was first discovered in 1958 in monkeys which was kept for research work — hence the name — with the first human case recorded in 1970, as per the CDC. Monkeypox can occur due to a bite by an infected animal, or by touching its blood, body fluids or fur. It is also possible to catch the disease by eating non-vegetarian food of an infected animal that has not been cooked properly. It is very unusual to catch monkeypox from a human as it does not spread conveniently between people. Notably, it is possible to spread the disease through touching clothing, bedding or towels utilized by someone with the rash. The disease can also be transmitted by touching monkeypox skin blisters or getting too close to coughs and sneezes from an infected person. Symptoms of money pox appear between 5-21 days of an infection in case of the first symptoms of an infection. Symptoms include a fever, a headache, muscle aches, backache, swollen glands, shivering and exhaustion. The rash is typically appearing one to five days after experiencing these symptoms. The rash is sometimes confused with chickenpox, owing to its appearance like raised spots which turn into small scabs filled with fluid. The symptoms usually clear up within two to four weeks and scabs falls off. The increasing number of cases across United Kingdom is driving the demand for money pox therapeutics.
However, high cost of monkeypox treatment and extensive investments on research activities is expected to impede the growth of the monkeypox therapeutics market during the forecast period.
Browse over XX market data Figures spread through 70 Pages and an in-depth TOC on “UNITED KINGDOM MONKEYPOX THERAPEUTICS MARKET“
The United Kingdom monkeypox therapeutics market is segmented into treatment, end user, regional distribution, and competitive landscape.
Based on treatment, the market is divided into smallpox vaccine, antivirals, vaccinia immune globulin (VIG). Smallpox vaccine segment is expected to hold the significant share in the market during the forecast period, 2023-2027. This is attributed to the fact that virus behind monkeypox and smallpox relatively same. Smallpox vaccines develops immunity and protect people from virus like this. This smallpox vaccine is made from the virus called Vaccinia. Vaccinia is the widely used virus which belong to the Orthopxvirus along with the variola virus. This virus is the live virus and not the killed or weakened virus so the people who are vaccinated should take precautions from the virus to spread.
Based on end user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, others. Hospitals segment holds the significant market share in the forecast period, 2023-2027. The increasing number of patients getting admitted in the hospital for the curable treatment of monkeypox rather than other healthcare systems, such as specialty clinics or Ambulatory Surgical Centers (ASCs) is fueling the segmental growth.
Key market players leading in the United Kingdom monkeypox therapeutics market are:
- Chimerix UK Limited
- SIGA Technologies, Inc.
- Emergent BioSolutions UK Ltd.
- Bavarian Nordic A/S
- Mylan N.V.
- Olon S.p.A.
- Teva UK Limited
Customers can also request for 10% free customization on this report.
“As per the study, it is found that virus behind monkeypox and smallpox is a close relative of the one that caused smallpox however, in comparison with the smallpox, money pox is less deadly and less transmissible. The virus occasionally spills over into humans, and infections like this have become more common in recent decades. The individual who are traveling to African countries are catching the symptoms of monkeypox and contacting with the infected people are spreading the monkeypox across the globe. Also, the monkeypox virus may be surreptitiously spreading from person to person, with some number of undetected cases. In addition to this, the incubation period between infection and symptoms is long, ranging from five to 21 days. This is further driving the need for therapeutics to combat with this virus and to stop it from spreading is expected to boost the growth for monkeypox therapeutics across United Kingdom till 2027” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm”.
“United Kingdom Monkeypox Therapeutics Market By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG)), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Competition Forecast & Opportunities, 2027 has analyzed the future growth potential of United Kingdom monkeypox therapeutics market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and assist decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with significant drivers, challenges, and opportunities in United Kingdom monkeypox therapeutics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com